Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$8.24
-$0.02(-0.33%)
At close: 4:00 PM EST
$8.24
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$3.96 - $9.92
Previous Close$6.08
Volume58.66K
Average Volume (3M)81.33K
Market Cap
$242.47M
Enterprise Value$311.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 06, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding27,831,697
10 Day Avg. Volume72,230
30 Day Avg. Volume81,326
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.75Price Target Upside66.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
International ExpansionEuropean and international advancement continuing with the acceptance of PEDMARQSI® by the Scottish Medicines Consortium (SMC) for use in Scotland.
Product AdoptionA large national oncology group has added PEDMARK to its formulary for patients under 40 years of age, signaling momentum for broader adoption in community settings.
Strategic MarketingFennec's refined marketing strategy and targeting of the AYA population seems to be materializing with a third consecutive quarter of sequential revenue growth and building recognition.
Bears Say
Market LimitationsDespite growing adoption, the target population for PEDMARK is relatively niche, focusing mainly on the AYA group, which might limit widespread market penetration.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $3.96 and its highest was $9.92 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $242.47M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -$0.108 earnings per share for the quarter, missing the consensus estimate of -$0.034 by -$0.075.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,831,697 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -$0.108 in its last earnings report, missing expectations of -$0.034. Following the earnings report the stock price went down -6.367%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
Fennec Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (66.87% Upside)
$13.75 (66.87% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $635.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.95%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.View all FENC earnings summariesFENC Stock 12 Month Forecast
Average Price Target
$13.75
▲(66.87% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
NervGen Pharma
―
Bright Minds Biosciences
―
Eupraxia Pharmaceuticals
―
Ownership Overview
16.36% Insiders
5.21% Mutual Funds
― Other Institutional Investors
72.11% Public Companies and
Individual Investors